ABCI3

ABCI3 (PF3D7_0319700) is a Plasmodium falciparum ABC-family membrane transporter that functions as a determinant of pleiotropic resistance to multiple structurally distinct antimalarial chemotypes (PMID:34233174). Resistance is achieved through two genetic mechanisms: point mutations in ABCI3 confer resistance to carboxamide-containing compounds, while gene amplification is selected by imidazopyridine and quinoline-carboxamide compounds, with the effect being strain-dependent (PMID:34233174). Reciprocal genetic manipulation supports a direct role: conditional knockdown or reduced ABCI3 expression increases parasite susceptibility to associated chemotypes, and gene editing confirms causality (PMID:34233174, PMID:39024967, PMID:41387370). ABCI3 does not act in isolation in the resistance landscape—it can operate epistatically with PfCRT and plasmepsins 2/3 to produce multigenic resistance, as resolved by genetic cross, bulk segregant analysis, and QTL mapping in humanized mice (PMID:37939186, PMID:37398288). The endogenous substrate and transport mechanism of ABCI3 have not been characterized in the available corpus; its role is defined entirely through drug-resistance phenotypes rather than a defined physiological transport function.

1. 2021 High

   Establishing which parasite factor accounts for resistance to a novel carboxamide chemotype series identified ABCI3 as a causal, genetically confirmed resistance determinant rather than a correlate.

   Evidence Resistance selection, gene editing, and conditional knockdown with heme fractionation readout in P. falciparum

   PMID:34233174

   Open questions at the time

   • The endogenous transported substrate of ABCI3 is not identified
   • The molecular mechanism by which point mutation versus amplification confers resistance is not resolved
   • The basis of strain-dependence is not defined
2. 2021 Medium

   Linking a second, structurally unrelated chemotype (DDD01034957) to ABCI3 tested whether the transporter's resistance role generalizes beyond carboxamides, supporting a pleiotropic function.

   Evidence In vitro resistance selection and whole genome sequencing in P. falciparum

   PMID:33479319

   Open questions at the time

   • No direct gene-editing confirmation reported in this study
   • Whether the same mutations mediate resistance across chemotypes is not established
3. 2023 High

   Determining whether ABCI3 acts alone or within a multigenic network showed it operates epistatically with PfCRT and plasmepsins 2/3, placing it in a combinatorial resistance architecture.

   Evidence P. falciparum genetic cross in humanized mice, bulk segregant analysis, QTL mapping, and gene editing

   PMID:37398288 PMID:37939186

   Open questions at the time

   • The biochemical nature of the interaction with PfCRT and plasmepsins 2/3 is not defined
   • Whether these factors converge on a shared substrate or pathway is unknown
4. 2024 Medium

   Extending the resistance association to pyrazolopyridine 4-carboxamides with a reciprocal knockdown readout reinforced that lowering ABCI3 restores compound potency, confirming its causal role for an additional chemotype.

   Evidence Resistance selection and ABCI3 knockdown coupled to a potency assay in P. falciparum

   PMID:39024967

   Open questions at the time

   • Single-lab result replicating a prior chemotype class
   • Mechanism linking transporter level to potency is not resolved
5. 2025 Medium

   Associating pyrimidine-2,4-diamine W482 resistance with ABCI3 amplification, and showing reduced expression increases susceptibility, demonstrated gene-dosage as a distinct resistance mechanism for another chemotype.

   Evidence Resistance selection, whole genome sequencing, and ABCI3 expression reduction with susceptibility assay in P. falciparum

   PMID:41387370

   Open questions at the time

   • Single-lab result
   • How copy-number increase translates to drug efflux or sequestration is not established

• The endogenous physiological substrate, direction of transport, and biochemical transport mechanism of ABCI3 remain unknown, as does the structural basis by which mutations and amplification confer resistance.
• No native substrate identified
• No structural or transport-mechanism model established
• Subcellular localization within the parasite not defined in the corpus